Harvard University (Shutterstock)

Alk­er­mes' head of ear­ly R&D jumps ship to new­ly cre­at­ed Har­vard role

Alk­er­mes’ head of ear­ly de­vel­op­ment is leav­ing the biotech for a new­ly cre­at­ed po­si­tion as ex­ec­u­tive di­rec­tor of ther­a­peu­tic trans­la­tion at Har­vard Med­ical School.

Mark Nam­chuk leaves af­ter 5 years as Alk­er­mes’ se­nior vice pres­i­dent of phar­ma­ceu­ti­cal and non-clin­i­cal de­vel­op­ment. His de­par­ture comes as Alk­er­mes re­ori­ents their R&D pro­gram af­ter high-pro­file strug­gles.

Nam­chuk’s job will be to lead the re­cent­ly cre­at­ed Har­vard Ther­a­peu­tics Ini­tia­tive. The hire is part of Har­vard’s in­creas­ing­ly com­mit­ted for­ay in­to biotech, one that in­cludes an Arie Bellde­grun-af­fi­lait­ed 36-acre re­search cam­pus and, with a con­sor­tium of col­lab­o­ra­tors, a blue­print­ed $50 mil­lion gene and cell ther­a­py cen­ter.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.